Carly Mallise

Dr. Carly Mallise

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Research in Developmental Disabilities
Verified
Journal Article
Closed access
CMCarly Mallise
Carly Mallise
ALAlison E. Lane
Alison E. Lane
AWAlix J. Woolard
Alix J. Woolard
OWOlivia M. Whalen
Olivia M. Whalen
VMVanessa E. Murphy
Vanessa E. Murphy
LCLinda E. Campbell
Linda E. Campbell

27 September 2021 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
PDF file
PCPaige Cornell
Paige Cornell
TATaylah Armstrong
Taylah Armstrong
RFRina Fyfe
Rina Fyfe
CMCarly Mallise
Carly Mallise
TDTracy Dudding-Byth
Tracy Dudding-Byth
LCLinda E. Campbell
Linda E. Campbell

29 July 2024 in Australian Occupational Therapy Journal
Verified
Journal Article
Closed access
KPKelsey Philpott‐Robinson
Kelsey Philpott‐Robinson
KHKirsti Haracz
Kirsti Haracz
DBDianne Blackwell
Dianne Blackwell
CMCarly Mallise
Carly Mallise
CLCarl Leonard
Carl Leonard
KWKylie Wales
Kylie Wales

13 September 2024 in Community Mental Health Journal
Verified
Journal Article
Open access
PDF file
CMCarly Mallise
Carly Mallise
LWLaura Wall
Laura Wall
FPFrancesco Paolucci
Francesco Paolucci
KDKate Davies
Kate Davies
GFGina La Hera Fuentes
Gina La Hera Fuentes
MHMilena Heinsch
Milena Heinsch
Mental health and substance use disorders affect the lives of many people worldwide. Prevention and treatment of these conditions is important for optimal health and wellbeing, yet service access barriers are common. Virtual models of care may help to reduce barriers to receiving care. However, to facilitate uptake and use of virtual services, they need to appeal to patients and clinicians. This systematic review aimed to synthesise preference elicitation studies to determine what features of virtual mental health and substance use care are preferred by service users and service providers. Following the PRISMA guidelines for systematic reviews, we searched PubMed, PsycINFO, EconLit, MEDLINE, CINAHL, Academic Search Ultimate, and ProQuest Central for all available studies from database inception until May 2023. The Mixed Methods Appraisal Tool was used to assess the methodological quality of included studies. Nineteen studies met the eligibility criteria. However, none examined preferences for elements of different models of virtual care. Across the included studies, we identified 41 unique features that mapped to four themes of mental health and substance use care (‘service’, ‘treatment’, ‘clinician’ and ‘additional supports’). Participant preferences were for individual, in-person, effective, flexible, and low-cost treatment. These preferences varied based on demographic factors, such as culture, gender, and participant type (e.g., patients, clinicians, general population). A user-centred approach should be adopted when designing and implementing mental health and substance use services. While preferences for features of mental health and substance use services more broadly are known, preferences for different models of virtual care remain unexplored. Future research should examine what features of virtual services would lead to optimal uptake and use across different users and stakeholders.

12 August 2024 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
DMDr. Vanessa Murphy
Dr. Vanessa Murphy
OWOlivia M. Whalen
Olivia M. Whalen
EWEvan Williams
Evan Williams
PGpeter gibson
peter gibson
LCLinda E. Campbell
Linda E. Campbell
KBKatherine Baines
Katherine Baines
Mothers with asthma or atopy have a higher likelihood of having autistic children, with maternal immune activation in pregnancy implicated as a mechanism. This study aimed to determine, in a prospective cohort of mothers with asthma and their infants, whether inflammatory gene expression in pregnancy is associated with likelihood of future autism. Mothers with asthma were recruited to the Breathing for Life Trial. RNA was extracted from blood samples collected at mid-pregnancy. 300 ng total RNA was hybridized with the nCounter Human Inflammation gene expression panel (Nanostring Technologies, 249 inflammation-related genes). Parents completed the First Year Inventory (FYI) at 12-month follow-up, which assessed an infant's likelihood for autism across 2 behavioural domains: social communication and sensory regulation. A total score ≥19.2 indicated increased likelihood for future autism. Inflammatory gene expression was profiled from 24 mothers: four infants scored in the high autism likelihood range; 20 scored in the low autism likelihood range. Six inflammatory genes were differentially expressed and significantly up-regulated in the high autism likelihood group: CYSLTR2, NOX1, C1QA, CXCL10, C8A, IL23R. mRNA count significantly correlated with social communication FYI score for CYSLTR2 (Pearson r = 0.46, p = 0.024) and CXCL10 (r = 0.43, p = 0.036) and with sensory regulation score for ALOX5 (r = -0.43, p = 0.038) and MAFK (r = -0.46, p = 0.022). In this proof-of-concept study, inflammatory gene expression during pregnancy in mothers with asthma was associated with an infant's likelihood of future autism as well as scores relating to social communication and sensory regulation.

1 May 2024 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
OWOlivia M. Whalen
Olivia M. Whalen
LCLinda E. Campbell
Linda E. Campbell
ALAlison E. Lane
Alison E. Lane
FKFrini Karayanidis
Frini Karayanidis
CMCarly Mallise
Carly Mallise
DMDr. Vanessa Murphy
Dr. Vanessa Murphy
Asthma during pregnancy is associated with a range of adverse perinatal outcomes. It is also linked to increased rates of neurodevelopmental conditions in the offspring. We aimed to assess whether fractional exhaled nitric oxide (FENO)-based asthma management during pregnancy improves child developmental and behavioural outcomes compared to usual care. The Breathing for Life Trial was a randomised controlled trial that compared FENO-based asthma management during pregnancy to usual care. Participants were invited to the developmental follow-up, the Breathing for Life Trial – Infant Development study, which followed up infants at 6 weeks, 6 months and 12 months. The primary outcomes were measured in infants at 12 months using the Bayley-III: Cognitive, Language and Motor composite scores. Secondary outcomes included Bayley-III social-emotional and adaptive behaviour scores, autism likelihood and sensory and temperament outcomes. The exposure of interest was the randomised intervention group. Two hundred and twenty-two infants and their 217 participating mothers were recruited to the follow-up; 107 mothers were in the intervention group and 113 were in the control group. There was no evidence of an intervention effect for the primary outcomes: Bayley-III cognitive (mean = 108.9 control, 108.5 intervention, p = 0.93), language (mean = 95.9 control, 95.6 intervention, p = 0.87) and motor composite scores (mean = 97.2 control, 97.9 intervention, p = 0.25). Mean scores for secondary outcomes were also similar among infants born to control and FENO group mothers, with few results reaching p < 0.05.Conclusion: In this sample, FENO-guided asthma treatment during pregnancy did not improve infant developmental outcomes in the first year of life.Trial registration: ClinicalTrials.gov Identifier: ACTRN12613000202763. What is Known:• Maternal asthma during pregnancy has been associated with increased rates of neurodevelopmental conditions in offspring, including intellectual disability and autism. What is New:• This is the first study to examine how managing asthma during pregnancy via a FENO-guided algorithm or usual care affects infant developmental and behavioural outcomes. While the results of the study showed no impact of the intervention, and therefore do not support the integration of FENO-based management of asthma in antenatal settings for optimal infant development, they do send a positive message about the implications of active asthma management during pregnancy on infant developmental outcomes.